Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis

Inclusion Criteria: * Diagnosis of RRMS according to the revised McDonald criteria (2017 or 2024 revisions). * Initiation of ocrelizumab s.c in accordance with routine clinical practice and local prescribing information. * The decision to initiate ocrelizumab s.c. has been made by the treating physician prior to and independently of study participation. * Willingness to complete the patient-reported outcome questionnaire TASQ, where applicable. Exclusion Criteria: * Participation in any clinical study involving disease modifying therapies for multiple sclerosis during the study period or at the time of enrollment. * Prior treatment with rituximab. * Contraindications to ocrelizumab as per the local prescribing information. * Severe psychiatric or cognitive impairment that, in the opinion of the treating physician, would preclude informed consent, reliable participation in the study, or completion of patient-reported outcomes. * Any condition which, in the opinion of the treating physician, would interfere with participation in the study or the interpretation of study results. * For participants participating in a Market Research and Patient Support Program (MAP), inclusion is permitted only when a cross-reference to the unique MAP patient identifier is available.